Brought to you by 
Schering gets non-US rights to Idec's Zevalin
31 Jan 2012
Executive Summary
Schering AG licensed exclusive worldwide marketing rights outside of the US to Idec's (monoclonal antibodies) Zevalin (ibritumomab tiuxetan, formerly IDEC-Y2B8) in a deal worth up to $47.5mm to Idec. Schering paid (uf)$13mm up front and will pay $15mm more in committed funds. Idec could also get $19.5mm more in milestones, as well as royalties on sales.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Schering gets non-US rights to Idec's Zevalin
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice